Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas (NCT03030066) | Clinical Trial Compass
Active — Not RecruitingPhase 1
Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas
Japan47 participantsStarted 2017-01-19
Plain-language summary
This is a study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of DS-1001b in patients with gliomas that harbor IDH1-R132 mutations.
Who can participate
Age range
20 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Has histologically confirmed glioma with an IDH1-R132 mutation
. Has disease that has recurred or progressed following standard treatment including radiotherapy
. Has measurable lesion(s) as per RANO criteria
. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Exclusion criteria
. Has significant symptoms of increased intracranial pressure
. Has another active neoplasm
. Has active infection requiring systemic treatment
. Has a history of severe cardiac disease
. Has had prior treatment with any inhibitor targeting mutant IDH1
. Has had investigational drug treatment within 4 weeks prior to the first dose of study treatment
. Is a pregnant or lactating female
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Percentage of participants with dose limiting toxicities